#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cluster headache Follicular lymphoma Alveolar rhabdomyosarcoma Amyotrophic lateral sclerosis gene carrier Superficial vein thrombosis Heart disease congenital Ependymoma Arterial tortuosity syndrome Infantile spasms Gastrooesophageal cancer Primary amyloidosis Endocrine ophthalmopathy Acute graft versus host disease in skin Encephalopathy neonatal Factor IX deficiency More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Diagnostics Factor IX deficiency – Life with Disease Mantle cell lymphoma stage IV – Treatment Langerhans cell sarcoma – Treatment Chronic granulomatous disease – Life with Disease Splenic marginal zone lymphoma – Life with Disease KBG syndrome – Basic Information Angiosarcoma metastatic – Diagnostics Basal cell naevus syndrome – Basic Information Ewing’s sarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Calcium Folinate Pp1493 Dabrafenib Leuprorelin Tramadol Hydrochloride Rhh646 Pasireotide Diaspartate Enfortumab Vedotin Relugolix Olorofim NORELGESTROMIN Idursulfase Tozorakimab Eteplirsen Quercus Ilex Allergen Extract Keto-Isoleucine Calcium Aup1602-C Cabotegravir Maralixibat Chloride Micafungin More therapies…

    Learn about Your Condition

    Erdheim-Chester disease Ovarian epithelial cancer B-cell lymphoma refractory Fibrous dysplasia of bone Ocular melanoma Fragile X syndrome Mastocytosis Vulvovaginal pruritus Alcohol abuse Chronic spontaneous urticaria Pouchitis Viral myocarditis Arrhythmia supraventricular Acarodermatitis Porphyria non-acute More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Eribulin
    • Izorlisib Mesilate
    Spain

  • Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Triple negative breast cancer
    Investigated Drugs:
    • Bevacizumab
    • Atezolizumab
    • Pertuzumab
    France

  • Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Carboplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Hungary +4

  • Study Comparing Sacituzumab Govitecan to Physician’s Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Carboplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Hungary +6

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Capecitabine
    • Carboplatin
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Nadunolimab
    • Carboplatin
    • Gemcitabine Hydrochloride
    Spain
Previous Page
1 … 7 8 9 10 11 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!